Clinical Trials Logo

Erectile Dysfunction clinical trials

View clinical trials related to Erectile Dysfunction.

Filter by:

NCT ID: NCT00848497 Terminated - Clinical trials for Erectile Dysfunction

Testosterone for Penile Rehabilitation After Radical Prostatectomy

Start date: November 2007
Phase: Phase 0
Study type: Interventional

The purpose of this study is to determine the effectiveness of testosterone replacement therapy (TRT) in men following surgery to remove the prostate in improving erectile function. Subjects will be randomized (like flipping a coin) to one of two groups. One group will receive Testim® (testosterone gel) 5 g per day plus Viagra 25 mg every night and the other will receive Placebo-Testim® 5 g per day plus Viagra 25 mg every night. Subjects will begin drug treatment 3 months after the initial screening visit and will take study drug for 3 months only. Participation will end at the end of the 6-month visit.

NCT ID: NCT00544076 Terminated - Prostate Cancer Clinical Trials

ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer

Start date: January 2006
Phase: Phase 3
Study type: Interventional

RATIONALE: Sildenafil citrate and alprostadil may help patients who have undergone prostatectomy for prostate cancer to recover from erectile dysfunction. PURPOSE: This randomized clinical trial is studying giving sildenafil together with alprostadil in treating patients undergoing nerve-sparing robotic-assisted radical prostatectomy for nonmetastatic prostate cancer.

NCT ID: NCT00351065 Terminated - Clinical trials for Male Erectile Dysfunction

Phase II Trial of SK3530 in Erectile Dysfunction

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This study was designed to evaluate the efficacy and safety of the SK3530 tablet and to find the optimal dose and dosage schedule after oral administration to patients with erectile dysfunction.

NCT ID: NCT00215631 Terminated - Prostate Cancer Clinical Trials

Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?

Start date: October 2005
Phase: Phase 3
Study type: Interventional

Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after external-beam radiotherapy, this patient category represents a most difficult therapeutic challenge. Therefore, prevention of ED could be more effective than treatment. Tadalafil, a new phosphodiesterase type 5 inhibitor, has been recently introduced. No studies have investigated the efficacy of tadalafil in preventing ED in patients undergoing radiotherapy for prostate cancer. Efficacy of tadalafil can last up to 36 hours after intake. This will result in a prolonged and continuos enhancement of penile vascular responsiveness. This randomized, double-blind, placebo-controlled study has been designed to evaluate the efficacy of 20-mg of tadalafil administered for 12 months in maintaining erectile function of potent patients undergoing external-beam radiotherapy for prostate cancer.